Ovarian Cancer's Earliest Sign Found in Blood

Researchers have identified a novel blood marker, Tu-stroma, capable of detecting the earliest warning signs of advanced ovarian cancer, which are typically undetectable by conventional imaging methods. This microscopic lesion, known as serous tubal intraepithelial carcinoma, signifies the initial development of high-grade serous ovarian cancer. The findings, published in Nature Medicine on November 10, 2026, could revolutionize ovarian cancer screening.

Ovarian cancer is notoriously difficult to detect early, often diagnosed in advanced stages, with only about 20 percent found early. The discovery of Tu-stroma, a molecule released by cancer cells that weakens neighboring healthy cells, offers a new avenue for detection. Studies indicated that a blood test measuring Tu-stroma could detect precancerous cases in approximately 92 percent of women with serous tubal intraepithelial carcinoma.

This advancement holds significant implications, particularly for women with an increased risk of ovarian cancer, including those with BRCA mutations. It offers the potential for earlier intervention and could avert drastic preventive measures like surgical removal of organs, which carry severe consequences for fertility and quality of life. While not yet ready for clinical use, researchers are preparing for prospective studies at Hoag Family Cancer Institute in Newport Beach, California, to validate these findings in larger cohorts.

Dr. Ronny Drapkin, not involved in the study, highlighted the transformative potential of detecting cancer at its nascent stages. He emphasized that this discovery underscores the importance of fundamental research in uncovering unexpected opportunities for early detection by understanding cancer's interaction with its environment. Further research will focus on confirming the test's ability to detect cancer before symptoms manifest.